Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (726)	9/11/2000 3:29:14 PM
From: dalroi	Read Replies (1) \| Respond to of 1475

RKRW Well well well RA, Crohn' did you see what enbrel did to IMNX market cap ? if this happens here i'll retire :-) :-) mc 160m --------21b$ or 120* should be nice Stefaan

To: rkrw who wrote (726)	9/11/2000 3:54:26 PM
From: scaram(o)uche	Respond to of 1475

>> How competitive will Medi-507 be with anti-CD11a? << 507 is postulated to selectively remove antigen-activated cells. There is experimental data to support this hope from in vitro experiments. It's a long stretch to what will happen in patients at low doses of the MAb. Anti-CD11a is designed to inhibit cell trafficking. IMO, one does not want to non-specifically muck with T cells if you don't need to, and they traffic for a reason. They traffic to defend us from viral and fungal diseases. Nonetheless, if I had severe issues with psoriasis, I wouldn't hesitate to try the anti-integrin approach. MEDI-507 could be the holy grail. It could be just another depleting antibody, useful only at high doses (and then only if it had demo'd advantages relative to other depleting antibodies). Perhaps someone at MEDI can now make that call, but...... to my knowledge, none of us can. <g> My stance is still the same..... if 507 hits big, it will hit monstrous.